Related references
Note: Only part of the references are listed.Genetic drivers of non-cutaneous melanomas: Challenges and opportunities in a heterogeneous landscape
Ismael A. Vergara et al.
EXPERIMENTAL DERMATOLOGY (2022)
Germline MBD4 Mutations and Predisposition to Uveal Melanoma
Anne-Celine Derrien et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
The Latest on Uveal Melanoma Research and Clinical Trials: Updates from the Cure Ocular Melanoma (CURE OM) Science Meeting (2019)
Vivian Chua et al.
CLINICAL CANCER RESEARCH (2021)
Clinical Proteomics of Metastatic Melanoma Reveals Profiles of Organ Specificity and Treatment Resistance
Lir Beck et al.
CLINICAL CANCER RESEARCH (2021)
Nivolumab Plus Ipilimumab for Treatment-Naive Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)
Jose Maria Piulats et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
UV-exposure, endogenous DNA damage, and DNA replication errors shape the spectra of genome changes in human skin
Natalie Saini et al.
PLOS GENETICS (2021)
Current molecular and clinical insights into uveal melanoma (Review)
Matteo Fallico et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2021)
Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study
Meredith S. Pelster et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
A prospective trial of adjuvant therapy for high-risk uveal melanoma: assessing 5-year survival outcomes
Elaine Binkley et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2020)
The Role of Immune Checkpoint Blockade in Uveal Melanoma
Anja Wessely et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development
Carlos R. Figueiredo et al.
JOURNAL OF PATHOLOGY (2020)
Single-cell analysis reveals new evolutionary complexity in uveal melanoma
Michael A. Durante et al.
NATURE COMMUNICATIONS (2020)
Identification of an immune-related signature for the prognosis of uveal melanoma
Ying-Zi Li et al.
INTERNATIONAL JOURNAL OF OPHTHALMOLOGY (2020)
Molecular profiling of driver events in metastatic uveal melanoma
Joakim Karlsson et al.
NATURE COMMUNICATIONS (2020)
Uveal melanoma
Martine J. Jager et al.
NATURE REVIEWS DISEASE PRIMERS (2020)
Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma
Nicholas D. Klemen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
The prognostic landscape of adaptive immune resistance signatures and infiltrating immune cells in the tumor microenvironment of uveal melanoma
Yijie Wang et al.
EXPERIMENTAL EYE RESEARCH (2020)
Development and validation of an immune and stromal prognostic signature in uveal melanoma to guide clinical therapy
Qianwen Gong et al.
AGING-US (2020)
Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma
Mark R. Middleton et al.
CLINICAL CANCER RESEARCH (2020)
Transcriptome Profiling Reveals New Insights into the Immune Microenvironment and Upregulation of Novel Biomarkers in Metastatic Uveal Melanoma
Yamini Krishna et al.
CANCERS (2020)
Presence of tumor-infiltrating CD8+ T cells and macrophages correlates to longer overall survival in patients undergoing isolated hepatic perfusion for uveal melanoma liver metastasis
Junko Johansson et al.
ONCOIMMUNOLOGY (2020)
Construction of immune-related risk signature for uveal melanoma
Zhaotian Zhang et al.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY (2020)
Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy
Yong Qin et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study
L. Khoja et al.
ANNALS OF ONCOLOGY (2019)
Evolutionary Routes in Metastatic Uveal Melanomas Depend on MBD4 Alterations
Manuel Rodrigues et al.
CLINICAL CANCER RESEARCH (2019)
Targeted Therapy of Uveal Melanoma: Recent Failures and New Perspectives
Michela Croce et al.
CANCERS (2019)
Synergic Interactions Between Hepatic Stellate Cells and Uveal Melanoma in Metastatic Growth
Leo Piquet et al.
CANCERS (2019)
Soluble HLA in the Aqueous Humour of Uveal Melanoma Is Associated with Unfavourable Tumour Characteristics
Annemijn P. A. Wierenga et al.
CANCERS (2019)
LBA71Phase II multicenter open label study of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study)
H Jespersen et al.
ANNALS OF ONCOLOGY (2019)
Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study
Markus Heppt et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma
Kalijn Fredrike Bol et al.
CANCERS (2019)
Secondary Somatic Mutations in G-Protein-Related Pathways and Mutation Signatures in Uveal Melanoma
Francesca Piaggio et al.
CANCERS (2019)
Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis
Elina S. Rantala et al.
MELANOMA RESEARCH (2019)
Immune cells in the retina and choroid: Two different tissue environments that require different defenses and surveillance
Paul G. McMenamin et al.
PROGRESS IN RETINAL AND EYE RESEARCH (2019)
Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma
Rene J. Tavera et al.
JOURNAL OF IMMUNOTHERAPY (2018)
Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors
Manuel Rodrigues et al.
NATURE COMMUNICATIONS (2018)
Real world experience in low-dose ipilimumab in combination with PD-1 blockade in advanced melanoma patients
Michael Constantin Kirchberger et al.
Oncotarget (2018)
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Frank Stephen Hodi et al.
LANCET ONCOLOGY (2018)
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Rodabe N. Amaria et al.
NATURE MEDICINE (2018)
Treatment of uveal melanoma: where are we now?
Jessica Yang et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
Inflammatory cell infiltrates in advanced metastatic uveal melanoma
Yamini Krishna et al.
HUMAN PATHOLOGY (2017)
Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study
Smita S. Chandran et al.
LANCET ONCOLOGY (2017)
Cellular and Molecular Mechanisms of Anterior Chamber-Associated immune Deviation (ACAID): what We Have Learned from Knockout Mice
Julie Vendomele et al.
FRONTIERS IN IMMUNOLOGY (2017)
Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study
Yong Qin et al.
ONCOIMMUNOLOGY (2017)
Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma
A. Gordon Robertson et al.
CANCER CELL (2017)
Genetic evolution of uveal melanoma guides the development of an inflammatory microenvironment
Gulcin Gezgin et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
The biology of uveal melanoma
Adriana Amaro et al.
CANCER AND METASTASIS REVIEWS (2017)
Identification of an Immunogenic Subset of Metastatic Uveal Melanoma
Luke D. Rothermel et al.
CLINICAL CANCER RESEARCH (2016)
Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4
Peter Johansson et al.
ONCOTARGET (2016)
Uveal melanoma: From diagnosis to treatment and the science in between
Chandrani Chattopadhyay et al.
CANCER (2016)
Metastatic ocular melanoma to the liver exhibits infiltrative and nodular growth patterns
Hans E. Grossniklaus et al.
HUMAN PATHOLOGY (2016)
Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma
Amanda R. Moore et al.
NATURE GENETICS (2016)
Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma
Kalijn F. Bol et al.
OPHTHALMOLOGY (2016)
Uveal Melanomas with SF3B1 Mutations A Distinct Subclass Associated with Late-Onset Metastases
Serdar Yavuzyigitoglu et al.
OPHTHALMOLOGY (2016)
Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas
Matthew G. Field et al.
ONCOTARGET (2016)
Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697)
David H. Lawson et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Clinical Characteristics of Uveal Melanoma in Patients With Germline BAP1 Mutations
Mrinali P. Gupta et al.
JAMA OPHTHALMOLOGY (2015)
Mutation frequencies of GNAQ, GNA11, BAP1, SF3B1, EIF1AX and TERT in uveal melanoma: detection of an activating mutation in the TERT gene promoter in a single case of uveal melanoma
M. Dono et al.
BRITISH JOURNAL OF CANCER (2014)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3
Marcel Martin et al.
NATURE GENETICS (2013)
Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma
J. William Harbour et al.
NATURE GENETICS (2013)
Good news-bad news: the Yin and Yang of immune privilege in the eye
John V. Forrester et al.
FRONTIERS IN IMMUNOLOGY (2012)
Different Subsets of Tumor-Infiltrating Lymphocytes Correlate with Macrophage Influx and Monosomy 3 in Uveal Melanoma
Inge H. G. Bronkhorst et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2012)
Impact of Clinical and Pathologic Features on Tumor-Infiltrating Lymphocyte Expansion from Surgically Excised Melanoma Metastases for Adoptive T-cell Therapy
Richard W. Joseph et al.
CLINICAL CANCER RESEARCH (2011)
Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas
J. William Harbour et al.
SCIENCE (2010)
Immune escape mechanisms of intraocular tumors
Jerry Y. Niederkorn
PROGRESS IN RETINAL AND EYE RESEARCH (2009)
PD-L1 Expression on Human Ocular Cells and Its Possible Role in Regulating Immune-Mediated Ocular Inflammation
Wanhua Yang et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2009)
BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization
Karen H. Ventii et al.
CANCER RESEARCH (2008)
Uveal melanoma expression of indoleamine 2,3-deoxygenase: Establishment of an immune privileged environment by tryptophan depletion
Peter W. Chen et al.
EXPERIMENTAL EYE RESEARCH (2007)
Loss of heterozygosity of chromosome 3 detected with single nucleotide polymorphisms is superior to monosomy 3 for predicting metastasis in uveal melanoma
Michael D. Onken et al.
CLINICAL CANCER RESEARCH (2007)
Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma
CS Vetter et al.
BRITISH JOURNAL OF CANCER (2004)
HLA expression in uveal melanoma: There is no rule without some exception
MJ Jager et al.
HUMAN IMMUNOLOGY (2002)
Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells
AC Repp et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
